Journal: Journal of nanobiotechnology

Article Title: Targeted delivery and ROS-responsive release of Resolvin D1 by platelet chimeric liposome ameliorates myocardial ischemia-reperfusion injury.

doi: 10.1186/s12951-022-01652-x

Figure Lengend Snippet: Fig. 1 Schematic of PLP-RvD1 fabrication and its targeting treatment for myocardial ischemia–reperfusion injury

Article Snippet: First, after 30 min treatment of BMDMs with 200 ul PBS, LP-RvD1 or PLP-RvD1, a pathological dose (100 uM) of H2O2 was administered to induce responsive release of RvD1, followed by incubation for 6 h. Second, HL-1 cardiomyocytes were induced to undergo apoptosis with 5 uM Staurosporine (HY-15141, Med Chem Express) after labeling with IVISense 680 Fluorescent Cell Labeling Dyes (NEV12000, Perkinelmer).

Techniques:

Journal: Journal of nanobiotechnology

Article Title: Targeted delivery and ROS-responsive release of Resolvin D1 by platelet chimeric liposome ameliorates myocardial ischemia-reperfusion injury.

doi: 10.1186/s12951-022-01652-x

Figure Lengend Snippet: Fig. 2 Preparation and Characteristics of PLP-RvD1. A TEM of PLP-RvD1. B Size of LPs, LP-RvD1 and PLP-RvD1 (n = 3 per group). C Zeta potential of LPs, LP-RvD1 and PLP-RvD1 (n = 3 per group). D Polymer dispersity index of LPs, LP-RvD1 and PLP-RvD1 (n = 3 per group). D Release profiles of RvD1 from nanovesicles (n = 3 per group). F Protein content visualization of PMVs and PLP-RvD1 running on SDS-PAGE at equivalent protein concentrations followed by Coomassie staining. G Western Blot of five key proteins in PLTs, PMVs, LP-RvD1, and PLP-RvD1 that mediate the interaction between PLTs and macrophages. H The glycosylated membrane proteins with correct orientation on PLTs, PMVs, LP-RvD1, and PLP-RvD1 were stained with Texas Red-X-conjugated WGA (n = 3 per group). All data expressed as Mean ± SD

Article Snippet: First, after 30 min treatment of BMDMs with 200 ul PBS, LP-RvD1 or PLP-RvD1, a pathological dose (100 uM) of H2O2 was administered to induce responsive release of RvD1, followed by incubation for 6 h. Second, HL-1 cardiomyocytes were induced to undergo apoptosis with 5 uM Staurosporine (HY-15141, Med Chem Express) after labeling with IVISense 680 Fluorescent Cell Labeling Dyes (NEV12000, Perkinelmer).

Techniques: Zeta Potential Analyzer, Polymer, SDS Page, Staining, Western Blot, Membrane

Journal: Journal of nanobiotechnology

Article Title: Targeted delivery and ROS-responsive release of Resolvin D1 by platelet chimeric liposome ameliorates myocardial ischemia-reperfusion injury.

doi: 10.1186/s12951-022-01652-x

Figure Lengend Snippet: Fig. 6 Cardiac protection efficiency of PLP-RvD1. A Cardiac function was assessed by echocardiography at 4 weeks after treatment (n = 6 per group). B Masson staining of MI/R heart paraffin sections at 4 weeks after various treatments. Scalar bar, 1 mm. C LVAW thickness and D fibrosis remodeling in (B) was quantified by using ImageJ software (n = 6 per group). Results are presented as mean ± SD. NSP > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001

Article Snippet: First, after 30 min treatment of BMDMs with 200 ul PBS, LP-RvD1 or PLP-RvD1, a pathological dose (100 uM) of H2O2 was administered to induce responsive release of RvD1, followed by incubation for 6 h. Second, HL-1 cardiomyocytes were induced to undergo apoptosis with 5 uM Staurosporine (HY-15141, Med Chem Express) after labeling with IVISense 680 Fluorescent Cell Labeling Dyes (NEV12000, Perkinelmer).

Techniques: Staining, Software

Journal: Journal of nanobiotechnology

Article Title: Targeted delivery and ROS-responsive release of Resolvin D1 by platelet chimeric liposome ameliorates myocardial ischemia-reperfusion injury.

doi: 10.1186/s12951-022-01652-x

Figure Lengend Snippet: Fig. 7 Biosafety verification of PLP-RvD1. A, B Serum concentration of inflammatory cytokines (IL-1β, TNF-α) of healthy mice detected by ELISA assay at 3 d post administration of PBS or PLP-RvD1 (n = 6 per group). C, D ELISA assay of immune response indicated by serum level of general IgG and IgM of healthy mice with or without PLP-RvD1 treatment (n = 6 per group). E Evaluation of the effect of PLP-RvD1 on clotting function (n = 6 per group). Biochemical test of F liver and G renal function of healthy mice after PBS or PLP-RVD1 administered (n = 6 per group). H Histology characteristics of major organs of PBS or PLP-RvD1 treated healthy mice were detected by HE staining. Scalar bar, 100 μm. Results are presented as mean ± SD. NSP > 0.05

Article Snippet: First, after 30 min treatment of BMDMs with 200 ul PBS, LP-RvD1 or PLP-RvD1, a pathological dose (100 uM) of H2O2 was administered to induce responsive release of RvD1, followed by incubation for 6 h. Second, HL-1 cardiomyocytes were induced to undergo apoptosis with 5 uM Staurosporine (HY-15141, Med Chem Express) after labeling with IVISense 680 Fluorescent Cell Labeling Dyes (NEV12000, Perkinelmer).

Techniques: Concentration Assay, Enzyme-linked Immunosorbent Assay, Coagulation, Staining

Journal: Journal of Neuroscience

Article Title: Resolvin D1 Programs Inflammation Resolution by Increasing TGF- Expression Induced by Dying Cell Clearance in Experimental Autoimmune Neuritis

doi: 10.1523/jneurosci.0020-16.2016

Figure Lengend Snippet: Figure 1. The temporal expression of resolvin D1 (RvD1), its synthetic enzyme, and its receptor in Experimental autoimmune neuritis (EAN) rats. A, EAN was induced in Lewis rats by active immunizationwithautoantigensandtheratsweremonitoreddailyforneurologicalsignsofEAN(n6).B,ELISAofRvD1andreal-timePCR(RT-PCR)analysisof12/15-LOXandALXinthesciatic nervesofnaiveandEANrats(n6).C,RepresentativeimmunostainingandsemiquantificationofALXinthesciaticnervesofnaiveandEANrats(n6).D,DoubleimmunostainingofALXinthe sciaticnervesofEANrats.ALXwasmainlyexpressedinCD68macrophages,butnotinW3/13TcellsorOX22Bcells.E,ELISAofRvD1andRT-PCRanalysisof12/15-LOXandALXinthedraining (inguinal) lymph nodes of naive and EAN rats. Representative data from at least two independent experiments are shown. Error bars indicate standard error of the mean (SEM). *p 0.05.

Article Snippet: In some cases, RvD1 was given together with SD-208 (a TGF- receptor antagonist; Santa Cruz Biotechnology, 20 mg/kg/d, i.p.) or SD-208 alone was given.

Techniques: Expressing, Reverse Transcription Polymerase Chain Reaction

Journal: Journal of Neuroscience

Article Title: Resolvin D1 Programs Inflammation Resolution by Increasing TGF- Expression Induced by Dying Cell Clearance in Experimental Autoimmune Neuritis

doi: 10.1523/jneurosci.0020-16.2016

Figure Lengend Snippet: Figure 3. Exogenous RvD1 treatment attenuated EAN. EAN rats were treated with RvD1 (5 g/kg/d, i.p.) or vehicle (0.9% endotoxin-free saline) from day 10 to day 22 after immunization. A, Neurological signs of EAN and body weight were monitored daily (n 6). B, Sciatic nerves of EAN rats were removed at day 22 for electron microscopy analysis and representative electron micrographs are shown. Arrows indicate axon demyelination (n 3). C, Representative immunohistochemistry staining and

Article Snippet: In some cases, RvD1 was given together with SD-208 (a TGF- receptor antagonist; Santa Cruz Biotechnology, 20 mg/kg/d, i.p.) or SD-208 alone was given.

Techniques: Saline, Electron Microscopy, Immunohistochemistry, Staining

Journal: Journal of Neuroscience

Article Title: Resolvin D1 Programs Inflammation Resolution by Increasing TGF- Expression Induced by Dying Cell Clearance in Experimental Autoimmune Neuritis

doi: 10.1523/jneurosci.0020-16.2016

Figure Lengend Snippet: Figure 5. RvD1 promoted inflammation resolution and disease recovery via TGF- in EAN rats. A, Protein level of TGF- in the sciatic nerves of EAN rats on day 22 that were treated with RvD1 (5g/kg/d),Boc-1(5mg/kg/d),orsalinefromday10today22afterimmunizationwasmeasuredbyELISA(n3).B–H,EANratsweretreatedwithsalinealone(control),RvD1(5g/kg/d,i.p.) togetherwithsalineortheTGF-receptorantagonistSD-208(20mg/kg/d,i.p.),orSD-208alonefromday10today22afterimmunization.RatsweremonitoreddailyforneurologicalsignsofEAN and body weight (B, n 6). C, Sciatic nerves from EAN rats on day 15 and day 22 were analyzed by electron microscopy; arrows indicate the axon demyelination (n 3). D, Representative immunohistochemistry staining and semiquantification of inflammatory cell infiltration in EAN sciatic nerves (n 3). E, mRNA levels of IFN-, (Figure legend continues.)

Article Snippet: In some cases, RvD1 was given together with SD-208 (a TGF- receptor antagonist; Santa Cruz Biotechnology, 20 mg/kg/d, i.p.) or SD-208 alone was given.

Techniques: Control, Electron Microscopy, Immunohistochemistry, Staining

Journal: Journal of Neuroscience

Article Title: Resolvin D1 Programs Inflammation Resolution by Increasing TGF- Expression Induced by Dying Cell Clearance in Experimental Autoimmune Neuritis

doi: 10.1523/jneurosci.0020-16.2016

Figure Lengend Snippet: Figure6. RvD1enhancedapoptoticcellphagocytosistoinduceTGF-inmacrophages.A,ProteinlevelofTGF-inCD68macrophagesfromthesciaticnervesofEANratsthatweretreatedwith RvD1(5g/kg/d,i.p.),Boc-1(5mg/kg/d,i.p.),orsalinefromday10today22afterimmunizationwasanalyzedbyflowcytometry(n3).B,RatperitonealmacrophageswereincubatedwithRvD1 for24hinvitroandtheTGF-proteinlevelinculturesupernatantsandthemRNAlevelinmacrophagesweremeasuredbyELISAandRT-PCR,respectively(n3).C,Ratperitonealmacrophages were treated with RvD1 together with CytD (2 M) or control for 24 h and fed with pHrodo-labeled apoptotic Jurkat cells for 1 h and the macrophage phagocytosis of apoptotic Jurkat cells was measuredbyflowcytometry(n3).D,RatperitonealmacrophageswereincubatedwithapoptoticJurkatcells(AJ),RvD1(250nM),CytD(2M),orcontrolfor24handtheTGF-proteinlevelin culture supernatants and the mRNA level in macrophages were measured by ELISA and RT-PCR, respectively (n 3). E, Rat peritoneal macrophages were incubated with RvD1 (250 nM) in the presence of apoptotic Jurkat cells (AJ) in vitro for 24 h and the mRNA levels of Arginase-1, TNF-, and IL-1 in macrophages were then analyzed by RT-PCR (n 3). F, Different concentrations of RvD1weredirectlyaddedtoJurkatcellculturesandincubatedfor24h;TGF-productionwasnotchanged.Representativedatafromatleasttwoindependentexperimentsareshown.Errorbars indicate SEM. *p 0.05.

Article Snippet: In some cases, RvD1 was given together with SD-208 (a TGF- receptor antagonist; Santa Cruz Biotechnology, 20 mg/kg/d, i.p.) or SD-208 alone was given.

Techniques: Control, Labeling, Enzyme-linked Immunosorbent Assay, Reverse Transcription Polymerase Chain Reaction, Incubation, In Vitro

Journal: Journal of Neuroscience

Article Title: Resolvin D1 Programs Inflammation Resolution by Increasing TGF- Expression Induced by Dying Cell Clearance in Experimental Autoimmune Neuritis

doi: 10.1523/jneurosci.0020-16.2016

Figure Lengend Snippet: Figure8. SchematicdiagramshowinghowRvD1increasesthemacrophagephagocytosisofapoptoticTcellstoinduceTGF-,promotinginflammationresolutionanddiseaserecoveryinEAN. RvD1,itssyntheticenzyme,anditsreceptorweregreatlyincreasedinthePNSduringtherecoverystageofEAN.TheenhancedRvD1pathwaypromotedthemacrophagephagocytosisofapoptotic T cells in the PNS, resulting in reduced apoptotic T-cell accumulation and the up-regulation of TGF- by macrophages. The induced TGF- enhanced Treg cell counts and inflammation resolution in the PNS, leading to disease recovery in EAN rats.

Article Snippet: In some cases, RvD1 was given together with SD-208 (a TGF- receptor antagonist; Santa Cruz Biotechnology, 20 mg/kg/d, i.p.) or SD-208 alone was given.

Techniques:

Journal: Drug Design, Development and Therapy

Article Title: 17(R)-RvD1 Ameliorates Liver Injury in Hyperuricemia Through Inhibiting Pyroptosis via NF-κB Signaling Pathway

doi: 10.2147/DDDT.S524747

Figure Lengend Snippet: 17(R)-RvD1 decreases serum uric acid, XOD, ALT and AST levels in hyperuricemia mice. ( A ) Experimental scheme: PO and hypoxanthine were injected intraperitoneally once a day, 17(R)-RvD1 was administered intraperitoneally every other day after modeling. The mice were euthanized on day 21 for subsequent analysis. ( B ) Uric acid, ( C ) XOD, ( D ) ALT and ( E ) AST levels in mice serum.

Article Snippet: 17(R)-RvD1, potassium oxonate, hypoxanthine, uric acid and LPS were purchased from MCE, without additional purification.

Techniques: Injection

Journal: Drug Design, Development and Therapy

Article Title: 17(R)-RvD1 Ameliorates Liver Injury in Hyperuricemia Through Inhibiting Pyroptosis via NF-κB Signaling Pathway

doi: 10.2147/DDDT.S524747

Figure Lengend Snippet: Effects of 17(R)-RvD1 on serum inflammatory cytokines levels in hyperuricemia mice. ( A ) IL-1β levels in mice serum detected by ELISA kit. ( B ) TNF-α levels in mice serum detected by ELISA kit. ( C ) IL-6 levels in mice serum detected by ELISA kit. ( D ) IL-18 levels in mice serum detected by ELISA kit.

Article Snippet: 17(R)-RvD1, potassium oxonate, hypoxanthine, uric acid and LPS were purchased from MCE, without additional purification.

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Drug Design, Development and Therapy

Article Title: 17(R)-RvD1 Ameliorates Liver Injury in Hyperuricemia Through Inhibiting Pyroptosis via NF-κB Signaling Pathway

doi: 10.2147/DDDT.S524747

Figure Lengend Snippet: 17(R)-RvD1 reduces hepatic inflammatory cytokines levels in hyperuricemia mice. ( A ) Histological analysis of liver tissues in mice. Scale bar 50 μm. ( B ) NAFLD activity score of livers in mice. ( C ) NLRP3 mRNA expression levels of livers in mice. ( D ) ASC mRNA expression levels of livers in mice. ( E ) Caspase-1 mRNA expression levels of livers in mice. ( F ) Hepatic c-caspase-1 levels in mice detected using ELISA kit. ( G ) Hepatic IL-1β levels in mice detected using ELISA kit. ( H ) Hepatic IL-18 levels in mice detected using ELISA kit.

Article Snippet: 17(R)-RvD1, potassium oxonate, hypoxanthine, uric acid and LPS were purchased from MCE, without additional purification.

Techniques: Activity Assay, Expressing, Enzyme-linked Immunosorbent Assay

Journal: Drug Design, Development and Therapy

Article Title: 17(R)-RvD1 Ameliorates Liver Injury in Hyperuricemia Through Inhibiting Pyroptosis via NF-κB Signaling Pathway

doi: 10.2147/DDDT.S524747

Figure Lengend Snippet: 17(R)-RvD1 improves uric acid-induced hepatocyte pyroptosis in LO2 cells. ( A ) Cell viability of LO2 cells. ( B ) LDH release of LO2 cells. ( C ) NLRP3 mRNA expression levels in LO2 cells. ( D ) ASC mRNA expression levels in LO2 cells. ( E ) Caspase-1 mRNA expression levels in LO2 cells. ( F ) GSDMD levels in LO2 cells measured using immunofluorescence. Scale bar 50 μm. ( G ) C-caspase-1 levels in LO2 cells measured using ELISA kit. ( H ) IL-1β levels in LO2 cells measured using ELISA kit. ( I ) IL-18 levels in LO2 cells measured using ELISA kit.

Article Snippet: 17(R)-RvD1, potassium oxonate, hypoxanthine, uric acid and LPS were purchased from MCE, without additional purification.

Techniques: Expressing, Immunofluorescence, Enzyme-linked Immunosorbent Assay

Journal: Drug Design, Development and Therapy

Article Title: 17(R)-RvD1 Ameliorates Liver Injury in Hyperuricemia Through Inhibiting Pyroptosis via NF-κB Signaling Pathway

doi: 10.2147/DDDT.S524747

Figure Lengend Snippet: 17(R)-RvD1 regulates LO2 cells pyroptosis by inhibiting NF-κB signaling pathway. ( A ) C-caspase-1 levels in LO2 cells exposed to uric acid following treatment with 17(R)-RvD1 or BAY 11–7082. ( B ) IL-1β levels in LO2 cells exposed to uric acid following treatment with 17(R)-RvD1 or BAY 11–7082. ( C ) IL-18 levels in LO2 cells exposed to uric acid following treatment with 17(R)-RvD1 or BAY 11–7082. ( D ) Representative Western blot images were shown on the left, graphic quantification of relative p-NF-κB p65 normalized to NF-κB p65 was shown on the right. ( E ) C-caspase-1 levels in LO2 cells exposed to uric acid following co-treatment with 17(R)-RvD1 and BAY 11–7082. ( F ) IL-1β levels in LO2 cells exposed to uric acid following co-treatment with 17(R)-RvD1 and BAY 11–7082. ( G ) IL-18 levels in LO2 cells exposed to uric acid following co-treatment with 17(R)-RvD1 and BAY 11–7082. ( H ) The speculative mechanism diagram of how 17(R)-RvD1 attenuates liver injury in hyperuricemia created using BioRender.

Article Snippet: 17(R)-RvD1, potassium oxonate, hypoxanthine, uric acid and LPS were purchased from MCE, without additional purification.

Techniques: Western Blot

Journal: Immunity, Inflammation and Disease

Article Title: Delayed Immune Response Upon Injury in Diabetic Wounds Impedes Healing

doi: 10.1002/iid3.70142

Figure Lengend Snippet: Early‐hours post wounding: MMP‐9 and Eicosanoids. (A) MMP‐9 expression within the wounded tissue at 6 h post wounding in the control ( n = 6) and diabetic ( n = 6) wounds. (B) The expression of the pro‐inflammatory lipid mediators, TxA2 (B.1), PGE2 (B.2) and LTB4 (B.3) as well as the expression of the (C) Specialized pro‐resolving lipid mediators MaR1 (C.1), RvE1 (C.2), RvD1 (C.3) and PD1 (C.4) within the wounded tissue at 6 h post wounding. Statistical analysis: Unpaired t ‐test. (D) Correlation matrix illustrating the significant R2‐values within the control and diabetic group respectively. (E) Spearman's correlation analysis indicating an inverse association between MMP‐9 and TxA2 (E.1), MaR1 (E.2), RvE1 (E.3), RvD1 (E.4) and PD1 (E.5) within the control groups, whereas no correlation was evident in the diabetic group.

Article Snippet: The concentration of thromboxane A2 (TxA2) (E‐EL‐0057, Elabscience), leukotriene B4 (LTB4) (E‐EL‐0061, Elabscience), prostaglandin E2 (PGE2) (E‐EL‐0034, Elabscience), protectin D1 (PD1) (ELK0497, ELK Biotechnology), maresin 1 (MaR1) (ELK0496, ELK Biotechnology), resolvin D1 (RvD1) (ELK0494, ELK Biotechnology), resolvin E1 (RvE1) (ELK0495, ELK Biotechnology) and matrix metalloproteinase ‐9 (MMP‐9) was assessed using either competitive or sandwiched based ELISA kits according to the manufacturer's instructions.

Techniques: Expressing, Control

Journal: Lipids in Health and Disease

Article Title: Assessment of plasma resolvin levels in women with breast cancer and their associations with disease presentation and immunohistochemical characteristics

doi: 10.1186/s12944-024-02386-5

Figure Lengend Snippet: Differences in plasma resolvin levels between patients with breast cancer and controls. The data revealed higher levels of resolvin D1 in breast cancer patients than in controls ( p = 0.015) (panel A). No differences were observed in resolvin D2, D3 or E1 levels between cancer patients and controls (panel B, C). Data are expressed as pg/ml and are presented as the median (95% CI). * p < 0.05

Article Snippet: All samples were analyzed via the commercially available ELISA kits (Mybiosource, Inc., San Diego, CA, USA): Human Resolvin D1 (RvD1) (Cat. No: MBS053145, sensitivity 5.0 pg/mL); Human Resolvin D2 (RvD2) (Cat. No: MBS051498, sensitivity 5.0 pg/mL); Human Resolvin D3 (RvD3) (Cat. No: MBS056544, sensitivity 2.0 pg/mL); and Resolvin E1 (RvE1) (Cat. No: MBS025958, sensitivity 5.0 pg/mL), in accordance with the manufacturer’s instructions reporting high sensitivity and excellent specificity ( https://www.mybiosource.com ).

Techniques: Clinical Proteomics

Journal: Lipids in Health and Disease

Article Title: Assessment of plasma resolvin levels in women with breast cancer and their associations with disease presentation and immunohistochemical characteristics

doi: 10.1186/s12944-024-02386-5

Figure Lengend Snippet: Linear correlations between plasma resolvin levels in breast cancer patients

Article Snippet: All samples were analyzed via the commercially available ELISA kits (Mybiosource, Inc., San Diego, CA, USA): Human Resolvin D1 (RvD1) (Cat. No: MBS053145, sensitivity 5.0 pg/mL); Human Resolvin D2 (RvD2) (Cat. No: MBS051498, sensitivity 5.0 pg/mL); Human Resolvin D3 (RvD3) (Cat. No: MBS056544, sensitivity 2.0 pg/mL); and Resolvin E1 (RvE1) (Cat. No: MBS025958, sensitivity 5.0 pg/mL), in accordance with the manufacturer’s instructions reporting high sensitivity and excellent specificity ( https://www.mybiosource.com ).

Techniques: Clinical Proteomics

Journal: Lipids in Health and Disease

Article Title: Assessment of plasma resolvin levels in women with breast cancer and their associations with disease presentation and immunohistochemical characteristics

doi: 10.1186/s12944-024-02386-5

Figure Lengend Snippet: Differences in plasma resolvin levels in the cancer group according to the form of presentation (sporadic, familiar and BRCA1/2 mutated groups). The data revealed lower levels of resolvin D1 in BRCA1/2-mutated patients than in the familiar and sporadic patients ( p = 0.031 and p = 0.020, respectively) (panel A). The data revealed lower levels of resolvin D3 in BRCA1/2-mutated patients than in the familiar and sporadic patients ( p = 0.031 and p = 0.013, respectively) (panel C). No difference was observed in the resolvins D2 and E1 levels among the three groups (panel B, D). Data are expressed as pg/ml and are presented as the median (95% CI). * p < 0.05

Article Snippet: All samples were analyzed via the commercially available ELISA kits (Mybiosource, Inc., San Diego, CA, USA): Human Resolvin D1 (RvD1) (Cat. No: MBS053145, sensitivity 5.0 pg/mL); Human Resolvin D2 (RvD2) (Cat. No: MBS051498, sensitivity 5.0 pg/mL); Human Resolvin D3 (RvD3) (Cat. No: MBS056544, sensitivity 2.0 pg/mL); and Resolvin E1 (RvE1) (Cat. No: MBS025958, sensitivity 5.0 pg/mL), in accordance with the manufacturer’s instructions reporting high sensitivity and excellent specificity ( https://www.mybiosource.com ).

Techniques: Clinical Proteomics

Journal: Lipids in Health and Disease

Article Title: Assessment of plasma resolvin levels in women with breast cancer and their associations with disease presentation and immunohistochemical characteristics

doi: 10.1186/s12944-024-02386-5

Figure Lengend Snippet: Differences in plasma resolvin levels between the sporadic plus familiar group and the BRCA1/2 mutated patient group. The data revealed lower levels of resolvin D1 and resolvin D3 in BRCA1/2-mutated patients than in the familiar plus sporadic patients ( p = 0.014 and p = 0.010, respectively) (panels A, C). Resolvin D2 and E1 levels tended to be lower in the BRCA1/2-mutated group than in the sporadic plus familiar group ( p = 0.051 and p = 0.062, respectively). Data are expressed as pg/ml and are presented as the median (95% CI). * p < 0.05

Article Snippet: All samples were analyzed via the commercially available ELISA kits (Mybiosource, Inc., San Diego, CA, USA): Human Resolvin D1 (RvD1) (Cat. No: MBS053145, sensitivity 5.0 pg/mL); Human Resolvin D2 (RvD2) (Cat. No: MBS051498, sensitivity 5.0 pg/mL); Human Resolvin D3 (RvD3) (Cat. No: MBS056544, sensitivity 2.0 pg/mL); and Resolvin E1 (RvE1) (Cat. No: MBS025958, sensitivity 5.0 pg/mL), in accordance with the manufacturer’s instructions reporting high sensitivity and excellent specificity ( https://www.mybiosource.com ).

Techniques: Clinical Proteomics

Journal: Lipids in Health and Disease

Article Title: Assessment of plasma resolvin levels in women with breast cancer and their associations with disease presentation and immunohistochemical characteristics

doi: 10.1186/s12944-024-02386-5

Figure Lengend Snippet: Differences in plasma resolvin D1 levels between triple-negative and nontriple-negative breast cancer patients. The data revealed lower levels of resolvin D1 in triple-negative patients than in non-triple-negative patients ( p = 0.023). Data are expressed as pg/ml and are presented as the median (95% CI). * p < 0.05

Article Snippet: All samples were analyzed via the commercially available ELISA kits (Mybiosource, Inc., San Diego, CA, USA): Human Resolvin D1 (RvD1) (Cat. No: MBS053145, sensitivity 5.0 pg/mL); Human Resolvin D2 (RvD2) (Cat. No: MBS051498, sensitivity 5.0 pg/mL); Human Resolvin D3 (RvD3) (Cat. No: MBS056544, sensitivity 2.0 pg/mL); and Resolvin E1 (RvE1) (Cat. No: MBS025958, sensitivity 5.0 pg/mL), in accordance with the manufacturer’s instructions reporting high sensitivity and excellent specificity ( https://www.mybiosource.com ).

Techniques: Clinical Proteomics

Journal: Lipids in Health and Disease

Article Title: Assessment of plasma resolvin levels in women with breast cancer and their associations with disease presentation and immunohistochemical characteristics

doi: 10.1186/s12944-024-02386-5

Figure Lengend Snippet: Differences in plasma resolvin D3 levels according to Ki-67% expression. The data revealed lower levels of resolvin D3 in breast cancer patients with high Ki-67 expression (≥ 20%) than in those with low Ki-67 expression ( p = 0.034). Data are expressed as pg/ml and are presented as the median (95% CI). * p < 0.05

Article Snippet: All samples were analyzed via the commercially available ELISA kits (Mybiosource, Inc., San Diego, CA, USA): Human Resolvin D1 (RvD1) (Cat. No: MBS053145, sensitivity 5.0 pg/mL); Human Resolvin D2 (RvD2) (Cat. No: MBS051498, sensitivity 5.0 pg/mL); Human Resolvin D3 (RvD3) (Cat. No: MBS056544, sensitivity 2.0 pg/mL); and Resolvin E1 (RvE1) (Cat. No: MBS025958, sensitivity 5.0 pg/mL), in accordance with the manufacturer’s instructions reporting high sensitivity and excellent specificity ( https://www.mybiosource.com ).

Techniques: Clinical Proteomics, Expressing

Journal: Translational Animal Science

Article Title: Effect of a dietary nutraceutical “STRUCTURE-Joint” on response of horses to intra-articular challenge with IL-1: implications for tissue adaptation to stress

doi: 10.1093/tas/txae172

Figure Lengend Snippet: Synovial fluid RvD1 following injection of IL-1 in healthy horses ( n = 8 per group) after 30 d of supplementation with 120 mL ST-J or an unsupplemented CON diet. * denotes significant difference from baseline within a single group; lower-case letters denote differences between groups at a single time point.

Article Snippet: Synovial fluid samples were then stored at −80 °C until analysis for PGE 2 (multispecies ELISA; Arbor Assays, Mississauga ON, CAT# K051-H5), glycosaminoglycan ( GAG ; dimethyl methylene blue assay; ), resolvin D1 ( RvD1 ; equine ELISA; AffiGen Life Science Supply Chain, Bailey’s Harbor WI; CAT# AFG-SB-7816), nitric oxide ( NO ; Griess Reaction; ), and chondroitin sulfate epitope 846 ( CS846 ; ELISA; IBEX, Montreal QC; CAT# 60-1004).

Techniques: Injection